No Data
No Data
China Gives Fusen Pharma Green Light for Traditional Chinese Drug Clinical Trial
China's medical products administrator accepted Fusen Pharmaceutical (HKG:1652) subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology's clinical trial application for the SY617 traditional
Fusen Pharm (01652.HK): The clinical trial application for innovative traditional Chinese medicine class 1.1 drug "SY 617" has been accepted.
On July 12th, Gelonhui reported that Fusen Pharm (01652.HK) announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Medical Technology Co., Ltd., has submitted a clinical trial application for its independently developed SY617 to the China National Medical Products Administration and has obtained acceptance. The function of SY617 is to disperse wind and detoxify, clear heat and eliminate dampness. It is used to treat wind-heat-dampness syndrome in the differentiation of epidemic influenza, with symptoms of fever, heavy head, sore throat, aversion to wind, cough, limb soreness, chest tightness, epigastric distension, red tongue with greasy coating or yellow coating, and slippery or rapid or floating pulse. According to Minet data, in 2022, respiratory system drug use.
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
FUSEN PHARM: SUPPLEMENTAL ANNOUNCEMENT TO THE 2023 CORPORATE GOVERNANCE REPORT
No Data